NetScout Systems (NTCT): Valuation Perspective Following New DDoS Threat Intelligence Report

If you are an investor weighing your next move on NetScout Systems (NTCT), their just-released research on DDoS attacks deserves your attention. The report maps out just how rapidly attack volume, sophistication, and global impact are climbing, especially in the wake of geopolitical tensions this year. By spotlighting how AI, botnets, and hacktivist groups are reshaping the threat landscape, NetScout aims to reinforce its credibility as a go-to source for cybersecurity intelligence. This focus could influence how the market views its future prospects.

Looking at the stock's numbers over the past year, there has been a fair amount of momentum. The shares are up 27% over the past year, and 15% just in the past month, hinting at building excitement potentially fueled by ongoing ransomware headlines and now this detailed new research. On a longer horizon, though, the stock is still recovering from a rough stretch, with a three-year return in negative territory, even as revenue has edged up slightly and net income has dipped.

After a year with clear upward momentum and a fresh reminder of NetScout’s expertise, some investors may be considering whether this is an opportunity to acquire shares at a compelling value, or whether the market already reflects expectations for rising cyber threats.

Advertisement

Most Popular Narrative: 3.9% Undervalued

The currently popular narrative sees NetScout Systems as modestly undervalued, with a fair value just above current trading levels based on future prospects.

Market optimism appears to be driven by strong recent growth in NetScout's cybersecurity segment. This is underpinned by customers prioritizing spending to counter increasingly complex and expanding cyber threats, which could lead investors to expect above-trend long-term revenue and earnings growth.

Curious to know what justifies NetScout’s higher price tag? This narrative leans on ambitious assumptions about growth, margins, and future earnings multiples. What is the bold forecast and what market tension makes these numbers possible? Find out how these surprising projections shape the fair value behind today's headlines.

Result: Fair Value of $25.82 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing cloud adoption and IT stack consolidation could disrupt NetScout’s legacy products. This may challenge the case for sustained high margins and robust growth.

Find out about the key risks to this NetScout Systems narrative.

Another View: What Does SWS DCF Model Suggest?

Our discounted cash flow calculation provides a different perspective on NetScout’s valuation. While the first method points to only modest upside, the SWS DCF model indicates the stock could be significantly undervalued. Which outlook best matches reality?

Look into how the SWS DCF model arrives at its fair value.

NTCT Discounted Cash Flow as at Sep 2025
NTCT Discounted Cash Flow as at Sep 2025

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out NetScout Systems for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own NetScout Systems Narrative

If you see things differently or want to start from your own analysis, keep in mind that creating your own perspective takes just minutes. Do it your way

A great starting point for your NetScout Systems research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Opportunities abound beyond NetScout Systems, and the smartest moves come from staying ahead. Be the investor who doesn’t just follow trends, but seizes them first using these powerful stock search tools:

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if NetScout Systems might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Kshitija Bhandaru

Kshitija Bhandaru

Kshitija (or Keisha) Bhandaru is an Equity Analyst at Simply Wall St and has over 6 years of experience in the finance industry and describes herself as a lifelong learner driven by her intellectual curiosity. She previously worked with Market Realist for 5 years as an Equity Analyst.

About NasdaqGS:NTCT

NetScout Systems

Provides carrier service assurance, cybersecurity, and Distributed Denial-of-Service (DDoS) solutions to protect digital business services against disruptions.

Flawless balance sheet and good value.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
44 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
65 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
22 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
23 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
CSBT.F logo
AnimalDoctorKwon on Kuros Biosciences ·

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Fair Value:US$342.1892.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
RZLV logo
European_Hidden_Gem_Stocks on Rezolve AI ·

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Fair Value:US$80.7897.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
EU
European_Hidden_Gem_Stocks
NET logo
European_Hidden_Gem_Stocks on Netcall ·

⚡ Two-Minute Drill: Netcall PLC - This £200M AI Stock Is Already Running the NHS

Fair Value:UK£2.1745.6% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
184 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0